Hypera S.A.

BOVESPA:HYPE3 Stock Report

Market Cap: R$11.4b

Hypera Past Earnings Performance

Past criteria checks 2/6

Hypera has been growing earnings at an average annual rate of 8%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 19.2% per year. Hypera's return on equity is 12.8%, and it has net margins of 20.2%.

Key information

8.0%

Earnings growth rate

7.9%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate19.2%
Return on equity12.8%
Net Margin20.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Nov 21
More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Nov 14
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

Oct 03
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Jul 13
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Jun 20
Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Revenue & Expenses Breakdown

How Hypera makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BOVESPA:HYPE3 Revenue, expenses and earnings (BRL Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247,7781,5702,5480
30 Jun 248,0011,6932,5070
31 Mar 248,0431,7042,5110
31 Dec 237,9151,6492,5210
30 Sep 238,1891,7722,5310
30 Jun 238,0861,7412,4920
31 Mar 237,7511,6942,3750
31 Dec 227,5461,7052,2990
30 Sep 227,0511,6402,1210
30 Jun 226,6481,6362,0170
31 Mar 226,2601,6601,9550
31 Dec 215,9371,6181,8950
30 Sep 215,4461,5771,8720
30 Jun 214,9021,4621,7560
31 Mar 214,4451,3821,6260
31 Dec 204,0891,3221,5640
30 Sep 203,8831,2431,5380
30 Jun 203,8031,1651,6050
31 Mar 203,7261,1061,6350
31 Dec 193,2951,1891,6110
30 Sep 193,2941,2521,5580
30 Jun 193,2331,2251,5080
31 Mar 193,1801,1641,4690
31 Dec 183,7241,1351,4810
30 Sep 183,7891,2881,5080
30 Jun 183,7161,2511,4770
31 Mar 183,6131,2001,4300
31 Dec 173,5001,1111,4100
30 Sep 173,2918191,3970
30 Jun 173,2267951,3800
31 Mar 173,2167431,3940
31 Dec 163,2286471,3720
30 Sep 163,2025571,3600
30 Jun 163,1294321,3390
31 Mar 163,0463491,3230
31 Dec 152,9573451,3070
30 Sep 151,5892637740
30 Jun 152,0393269440
31 Mar 152,4473601,0950
31 Dec 142,7683381,2450
30 Sep 144,4984001,9130
30 Jun 144,4233571,8630
31 Mar 144,3592491,8510
31 Dec 134,2592591,8040

Quality Earnings: HYPE3 has high quality earnings.

Growing Profit Margin: HYPE3's current net profit margins (20.2%) are lower than last year (21.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HYPE3's earnings have grown by 8% per year over the past 5 years.

Accelerating Growth: HYPE3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HYPE3 had negative earnings growth (-11.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.7%).

Return on Equity

High ROE: HYPE3's Return on Equity (12.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hypera S.A. is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Georgia JorgeBB Banco de Investimento S.A.
Andréa AznarBB Banco de Investimento S.A.
Robert Ford AguilarBofA Global Research